

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/967827/publications.pdf>

Version: 2024-02-01

25  
papers

1,334  
citations

840776

11  
h-index

610901

24  
g-index

25  
all docs

25  
docs citations

25  
times ranked

1583  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dissociated humoral and cellular immune responses after a three-dose schema of BNT162b2 vaccine in patients receiving anti-CD20 monoclonal antibody maintenance treatment for B-cell lymphomas. <i>Haematologica</i> , 2022, 107, 755-758.	3.5	6
2	Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 351-363.	27.0	278
3	Targeting CD19 in diffuse large B-cell lymphoma: An expert opinion paper. <i>Hematological Oncology</i> , 2022, 40, 505-517.	1.7	7
4	Asia subpopulation analysis from the phase III POLARIX trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7558-7558.	1.6	0
5	Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).. <i>Journal of Clinical Oncology</i> , 2022, 40, 7551-7551.	1.6	1
6	Polatuzumab vedotin, an anti-CD79b antibody-drug conjugate for the treatment of relapsed/refractory diffuse large B-cell lymphoma. <i>Future Oncology</i> , 2021, 17, 127-135.	2.4	6
7	EHA/ESMO Clinical Practice Guidelines for the Management of Malignant Lymphoma: Recommendations for the Second Phase of the COVID-19 Pandemic. <i>HemaSphere</i> , 2021, 5, e529.	2.7	11
8	Angiogenesis imaging study using interim [18F] RGD-K5 PET/CT in patients with lymphoma undergoing chemotherapy: preliminary evidence. <i>EJNMMI Research</i> , 2021, 11, 37.	2.5	3
9	CNS relapse in DLBCL patients below 60 years treated with R-ACVBP, R-CHOEP, or R-CHOP: A joint analysis of LYSA and GLA/DSHNHL.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7543-7543.	1.6	3
10	Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory indolent non-Hodgkin's lymphoma (R/R iNHL): Primary analysis of a phase 2 trial from LYSA.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7544-7544.	1.6	3
11	The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, LBA-1-LBA-1.	1.4	5
12	Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study. <i>Haematologica</i> , 2020, 106, 154-162.	3.5	58
13	Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8053-8053.	1.6	8
14	Double Hit Lymphoma Diagnosis and Treatment in Europe – A Cross-Sectional Survey of Clinical Practice by the EHA Lymphoma Working Party (EHA LyG). <i>HemaSphere</i> , 2020, 4, e481.	2.7	3
15	Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review. <i>Leukemia and Lymphoma</i> , 2019, 60, 1610-1625.	1.3	16
16	Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b/2 study. <i>Lancet Oncology</i> , The, 2019, 20, 998-1010.	10.7	101
17	Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). <i>Lancet Haematology</i> , the, 2019, 6, e254-e265.	4.6	184
18	Response to A+CHP by CD30 expression in the ECHELON-2 trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7538-7538.	1.6	3

#	ARTICLE	IF	CITATIONS
19	Comparison of clinical scoring systems in aggressive B-cell lymphomas (BCL): An individual patient-level analysis across international trials (SEAL).. Journal of Clinical Oncology, 2019, 37, 7544-7544.	1.6	3
20	Managing early failures with R-CHOP in patients with diffuse large B-cell lymphoma. Expert Review of Hematology, 2017, 10, 1047-1055.	2.2	8
21	Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma. Haematologica, 2016, 101, 1094-1101.	3.5	97
22	Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis. Haematologica, 2015, 100, e280-e284.	3.5	69
23	Safety and activity of the anti-CD79B antibody drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncology, The, 2015, 16, 704-715.	10.7	272
24	Therapeutic options in relapsed or refractory peripheral T-cell lymphoma. Cancer Treatment Reviews, 2014, 40, 1080-1088.	7.7	58
25	Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. Haematologica, 2013, 98, 1726-1731.	3.5	131